Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
NEW YORK , Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
09:38am, Thursday, 18'th Sep 2025
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) investors o
It Is Time To Buy Novo Nordisk Hand Over Fist
09:36am, Thursday, 18'th Sep 2025
Novo Nordisk A/S remains a Strong Buy, driven by restructuring, pipeline advancements, and robust product developments like the Wegovy pill. NVO's restructuring will cut 9,000 jobs, saving $1.27B annu
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
08:57am, Thursday, 18'th Sep 2025
Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit - NVO
08:45am, Thursday, 18'th Sep 2025
NEW YORK , Sept. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk shares rise 5% on upbeat analyst reaction to diabetes conference
06:13am, Thursday, 18'th Sep 2025
Novo Nordisk shares rose 5% on Thursday following positive analyst reactions to an investor meeting that company executives held at the European Association for the Study of Diabetes conference.
Novo Nordisk Stock Jumps. New Ozempic Data for Seniors Beats Rival Eli Lilly Medicine.
06:10am, Thursday, 18'th Sep 2025
In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of heart attack, stroke and death by 23% compared with an older drug.
Bagsværd, Denmark, 18 September 2025 – Novo Nordisk today announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, Ozempic® (once-weekly injectable semag
Novo Nordisk's Wegovy Pill Shows Similar Weight-Loss to Its Shot, Study Finds
02:41am, Thursday, 18'th Sep 2025
Production is under way and the pill, which helped patients lose an average 16.6% of their weight, is pending regulatory approval in the U.S.
Wegovy pill offers 'significant' weight reduction, Novo Nordisk says, as oral obesity drug race intensifies
02:16am, Thursday, 18'th Sep 2025
Trial results showed the "Wegovy pill" led to average weight reduction of 16.6% after 64 weeks, Novo Nordisk said. The company's Chief Science Officer Martin Holst Lange told CNBC that oral treatment
NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
06:57pm, Wednesday, 17'th Sep 2025
NEW YORK , Sept. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025
Market delayed in reaction to Novo Nordisk and Eli Lilly' s GLP-1 pills, says Mizuho's Jared Holz
06:14pm, Wednesday, 17'th Sep 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk competition in the GLP-1 pill space between Novo Nordisk and Eli Lilly.
Novo Nordisk A/S - Special Call
05:33pm, Wednesday, 17'th Sep 2025
Novo Nordisk A/S - Special Call Company Participants Martin Lange - EVP of R&D, CSO and Member of the Management Board Conference Call Participants Martin Parkhoi - SEB, Research Division Michael Novo
Novo Nordisk says Wegovy pill shows comparable weight-loss to injectable version
05:26pm, Wednesday, 17'th Sep 2025
Novo Nordisk's experimental Wegovy pill showed a 16.6% weight-loss in a late-stage study, according to data published in The New England Journal of Medicine on Wednesday, which is comparable to previo
Novo Nordisk's oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
05:05pm, Wednesday, 17'th Sep 2025
Bagsværd, Denmark, Plainsboro, NJ, 17 September 2025 – Today, The New England Journal of Medicine published the results from the OASIS 4 phase 3 trial that studied the efficacy and safety of the in
